Polycythemia Vera
Polycythemia vera is a clonal stem cell neoplasm originating from the myeloid lineage. Epidemiologically, it has an incidence of approximately $1:100,000$, most commonly affecting men over the age of 40.
The core pathogenesis involves a marked increase in red blood cell production. However, the process is not restricted to erythroid cells alone; it is typically accompanied by the excessive proliferation of the granulocytic and megakaryocytic lineages.
Diagnostic laboratory findings for polycythemia vera include:
- Marked elevation of total red blood cell mass (exceeding $7 \times 10^{12}/\text{L}$).-
- High hemoglobin levels, typically rising above $180 \text{ g/L}$.
- Corresponding elevation in hematocrit.
The clinical outcome is largely dictated by altered hemorheology and increased blood viscosity. Patients are at high risk of mortality from severe complications directly linked to hypertension and fatal thrombotic events.
Primary Myelofibrosis
In clinical literature, this condition has several synonyms: subleukemic myelosis, aleukemic myelosis, and osteomyelosclerosis.
The pathogenesis follows a sequential cascade:
- Primary clonal proliferation occurs within the bone marrow, primarily involving the megakaryocytic and granulocytic pools.
- The abnormal megakaryocytes and circulating platelets release high levels of specific growth factors.
- These factors act as potent stimuli for fibroblast activation, resulting in the massive deposition of reticulin and collagen fibers, which leads to severe bone marrow fibrosis.
The peripheral blood picture in myelofibrosis contrasts sharply with polycythemia, often demonstrating pancytopenia—a total reduction in all blood cell lineages. The prognosis remains guarded, as approximately 10% of cases undergo transformation into acute leukemia.
Essential Thrombocythemia
Essential thrombocythemia is a rare hematologic disorder. Its morphological hallmark is pronounced megakaryocytic hyperplasia, which predictably results in the overproduction of platelets.
Laboratory findings in this condition are distinct:
- Platelet counts in peripheral blood reach extreme values, frequently exceeding $1000 \times 10^9/\text{L}$.
- Concomitant neutrophil leukocytosis is often observed.
The clinical presentation has a paradoxical feature: despite the high platelet count, a leading manifestation is bleeding. This occurs because the massive pool of circulating platelets possesses severe functional defects that impair normal hemostasis.
Disease progression can take two main paths: most commonly, transformation into myelofibrosis, and less frequently, progression to acute myeloid leukemia.
Borderline and Rare Forms
The classification also encompasses rare forms of chronic leukemias, such as chronic neutrophilic leukemia and chronic eosinophilic leukemia (the latter also known as hypereosinophilic syndrome).
A special category includes myelodysplastic/myeloproliferative neoplasms, which are a broad group bridging different overlapping disorders of the hematopoietic system. This group includes:
- Chronic myelomonocytic leukemia.
- Atypical chronic myeloid leukemia.
- Juvenile myelomonocytic leukemia.